Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Tuesday

Black Diamond Therapeutics (NASDAQ:BDTX) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 11, 2025 at 7:00 AM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its earnings results on Thursday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Stock Performance

BDTX opened at $3.87 on Monday. The company’s 50 day simple moving average is $3.50 and its 200 day simple moving average is $2.76. Black Diamond Therapeutics has a 1 year low of $1.20 and a 1 year high of $4.45. The stock has a market capitalization of $220.36 million, a PE ratio of 16.83 and a beta of 3.12.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BDTX shares. Zacks Research cut shares of Black Diamond Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Black Diamond Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of Black Diamond Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Stifel Nicolaus assumed coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, October 15th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Wall Street Zen cut shares of Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Black Diamond Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

Institutional Trading of Black Diamond Therapeutics

A number of hedge funds have recently made changes to their positions in BDTX. Invesco Ltd. raised its stake in shares of Black Diamond Therapeutics by 152.5% during the first quarter. Invesco Ltd. now owns 45,989 shares of the company’s stock valued at $71,000 after purchasing an additional 27,777 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Black Diamond Therapeutics during the first quarter valued at approximately $84,000. American Century Companies Inc. purchased a new stake in shares of Black Diamond Therapeutics during the second quarter valued at approximately $30,000. Prudential Financial Inc. purchased a new stake in shares of Black Diamond Therapeutics during the second quarter valued at approximately $32,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Black Diamond Therapeutics during the second quarter valued at approximately $343,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.